The results showed that there was a higher proportion of patients who did not receive radiotherapy among the PAAD patients with high expression of SUMO2 (Figure 2A) (Supplementary Material S1), while there was a higher proportion of patients with a history of smoking, higher tumor grade, and higher tumor stage among the PAAD patients with high expression of SUMO3 (Figure 2A) (Supplementary Material S1). Here, SUMO2 is linked to pancreatic adenocarcinoma.